UBS flags Rio Tinto's copper gap, points to Los Azules

What happened

UBS, rating Rio Tinto at Neutral with a 7,300p target, warns the miner may need to expand its copper pipeline to avoid a growth gap after 2030, identifying Argentina's Los Azules project as a potential solution. Rio is on track to lift copper output from 883kt in 2025 to ~1Mt by 2030, aided by Oyu Tolgoi and Kennecott, but this still implies a near-term trough in 2026 guidance of 800–870kt. The DeepValue report's WAIT rating and $98.50 price reflect that the stock already prices in a copper-led re-rating, yet iron ore still drives the majority of EBITDA and cash flow. With net debt rising to $14.6B by mid-2025 and free cash flow shrinking, Rio needs stronger copper volume visibility and cost proof to justify the current valuation. The UBS note reinforces the market's focus on copper growth, but does not change the near-term reliance on iron ore stability and execution risk at Oyu Tolgoi.

Implication

UBS's neutral rating and identification of Los Azules underscore that Rio's copper pipeline needs strengthening beyond current Oyu Tolgoi plans to sustain growth post-2030. For investors, the immediate takeaway is that 2026 copper output is expected to decline year-over-year, creating a near-term headwind to the re-rating story. The DeepValue report's WAIT rating remains appropriate: the stock already prices in optimistic copper execution, while iron ore headwinds (China steel demand -1% in 2026, Simandou supply) and rising net debt limit upside. A clearer 2027 copper volume bridge and proof of Pilbara cost control are needed to justify a higher entry. Until then, risk-adjusted returns favor waiting for either a lower entry near $85 or concrete proof points in the next earnings cycle.

Thesis delta

The UBS article does not challenge the existing thesis; it merely adds a medium-term copper growth need. The core investment case remains unchanged: Rio's valuation embeds a copper pivot that lacks near-term volume proof, while iron ore cash generation is under pressure from declining China demand and rising costs. No shift in the WAIT rating or conviction is warranted.